TransMedics Group, Inc. (TMDX)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
$89.98+3.45%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
QuarterlyIQ Insights · TMDX
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | |
|---|---|---|---|---|---|---|---|---|
| Revenues | ||||||||
| Revenues | 668.5 | 605.5 | 441.5 | 241.6 | 93.5 | 30.3 | 25.6 | 23.6 |
| Total Revenues | 668.5 | 605.5 | 441.5 | 241.6 | 93.5 | 30.3 | 25.6 | 23.6 |
| Cost of Revenues | 276.1 | 242.7 | 179.5 | 87.5 | 28.2 | 9.1 | 9.0 | 9.7 |
| Gross Profit | 392.3 | 362.8 | 262.1 | 154.1 | 65.3 | 21.2 | 16.6 | 13.9 |
| Operating Expenses & Income | ||||||||
| Selling, General & Admin | 218.3 | 185.2 | 168.6 | 119.6 | 69.9 | 38.3 | 24.2 | 23.6 |
| R&D Expenses | 92.5 | 69.1 | 56.0 | 36.1 | 26.8 | 22.3 | 18.8 | 19.9 |
| Operating Income | 81.6 | 108.6 | 37.5 | (28.7) | (31.4) | (39.4) | (26.4) | (29.6) |
| Earnings from Continuing Operations | ||||||||
| Interest Expense | — | 13.8 | 14.4 | 10.8 | 3.7 | 3.9 | 4.0 | 4.4 |
| Other Non-Operating Income / Expenses | (9.1) | (1.1) | (1.7) | 2.1 | (4.7) | (4.8) | (2.3) | (3.9) |
| EBT, Incl. Unusual Items | 72.6 | 107.5 | 35.8 | (26.7) | (36.2) | (44.2) | (28.7) | (33.5) |
| Income Tax Expense | (79.1) | (82.8) | 0.3 | (1.6) | 0.1 | — | 0.0 | 0.0 |
| Net Income | ||||||||
| Net Income | 151.7 | 190.3 | 35.5 | (25.0) | (36.2) | (44.2) | (28.7) | (33.5) |
| Per Share | ||||||||
| Basic EPS | 4.39 | 5.60 | 1.07 | (0.77) | (1.23) | (1.60) | (1.16) | — |
| Diluted EPS | 3.73 | 4.87 | 1.01 | (0.77) | (1.23) | (1.60) | (1.16) | — |
| Revenue per Share | 16.42 | — | — | — | — | — | — | — |
| Dividend per Share | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic Weighted Avg Shares | 34.6 | 34.0 | 33.2 | 32.5 | 29.6 | 27.6 | 24.7 | — |
| Diluted Weighted Avg Shares | 40.7 | 40.5 | 35.2 | 32.5 | 29.6 | 27.6 | 24.7 | — |
| Supplemental | ||||||||
| EBITDA | — | 135.8 | 57.3 | (20.6) | (28.0) | (37.6) | (24.8) | (28.4) |
| EBIT | 81.6 | 108.6 | 37.5 | (28.7) | (31.4) | (39.4) | (26.4) | (29.6) |
| Effective Tax Rate | -109.1% | — | — | 6.2% | -0.2% | — | 0.0% | 0.0% |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.